NDA 217766, held by Long Grove Pharms. Vasopressin.
As of Nov 13, 2026, NDA 217766 (Vasopressin In Sodium Chloride 0.9%), held by Long Grove Pharms, was first approved by FDA on Jul 11, 2024, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 11, 2024 | Original applicationNew dosage form · Standard review | Approved |
| Vasopressin In Sodium Chloride 0.9%20UNITS/100ML (0.2UNITS/ML) · solution;intravenous | Vasopressin | RxReference drug |
| Vasopressin In Sodium Chloride 0.9%40UNITS/100ML (0.4UNITS/ML) · solution;intravenous | Vasopressin | RxReference drug |
| Vasopressin In Sodium Chloride 0.9%50UNITS/50ML (1UNIT/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · solution;intravenous | Vasopressin | DiscontinuedReference drug |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
